Skip to content
Peptigraph home
Shop Peptides50% off*

Does PT-141 work for women?

For premenopausal women with low sexual desire, yes in trials: the integrated phase 3 analysis found desire scores 0.35 points higher than on placebo on the FSFI desire domain.

Melanocortin agonistUpdated

Short answer

For premenopausal women with low sexual desire, yes in trials: the integrated phase 3 analysis found desire scores 0.35 points higher than on placebo on the FSFI desire domain.[1]

The same analysis found distress about low desire fell by 0.33 points more than on placebo.[1]

Who the evidence covers

The benefit held across age, weight and BMI subgroups of the phase 3 trials.[2]

The approved product is indicated only for premenopausal women with acquired, generalized hypoactive sexual desire disorder.[3]

The label states it is not indicated for postmenopausal women or for men, and not to enhance sexual performance.[3]

What women reported and what it cost

In exit interviews, women who received bremelanotide described more sexual desire, physical arousal and better quality of sexual activity with their partner.[4]

The label reports nausea in 40% of patients, with 8% stopping early because of it.[3]

Common questions

What does PT-141 do for women?

In premenopausal women with low desire, it raised desire scores and lowered distress about low desire compared with placebo in phase 3 trials.[1]

More questions on PT-141

Does PT-141 make you tan?What does PT-141 do for men?

More on PT-141

ResultsStudy outcomes and when they were measured.PT-141 overview

Sources

  1. 1Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials.Obstetrics and gynecology · 2019PMID 31599840Accessed 2 Oct 2026
  2. 2Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide.Journal of women's health (2002) · 2022PMID 35230162Accessed 2 Oct 2026
  3. 3VYLEESI prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
  4. 4The Patient Experience of Premenopausal Women Treated with Bremelanotide for Hypoactive Sexual Desire Disorder: RECONNECT Exit Study Results.Journal of women's health (2002) · 2021PMID 33538638Accessed 2 Oct 2026

Found an error? Report a correction.